Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Jessica Notohardjo

Citation

Annals of Oncology (2019) 30 (suppl_5): v325-v355. 10.1093/annonc/mdz248

Authors

J.C..L. Notohardjo1, M.C.P. Kuppen2, H.M. Westgeest3, A.J.M. van den Eertwegh1, J. Van Moorselaar4, N. Mehra5, J..L. Coenen6, I. van Oort7, A.C.M. van den Bergh8, K.K.H. Aben9, D.M. Somford10, R. de Wit11, A.M. Bergman12, L. Lavalaye13, C. Uyl-de Groot14, W.R. Gerritsen15

Author affiliations

  • 1 Department Of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, 1081 HV - Amsterdam/NL
  • 2 Institute For Medical Technology Assessment, Erasmus School of Health Policy and Management, 3062 PA - Rotterdam/NL
  • 3 Department Of Internal Medicine, Amphia Hospital, 4819 EV - Breda/NL
  • 4 Department Of Urology, Amsterdam UMC, Vrije Universiteit, 1081 HV - Amsterdam/NL
  • 5 Department Of Medical Oncology, Radboud University Medical Center, 6525 GA - Nijmegen/NL
  • 6 Department Of Medical Oncology, Isala, 8025 AB - Zwolle/NL
  • 7 Department Of Urology, Radboud University Medical Center, 6525 GA - Nijmegen/NL
  • 8 Department Of Radiation Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ - Groningen/NL
  • 9 Department Of Research, Netherlands Comprehensive Cancer Organization, 6533AA - Nijmegen/NL
  • 10 Department Of Urology, Canisius Wilhemina Ziekenhuis, 6532 SZ - Nijmegen/NL
  • 11 Department Of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075EA - Rotterdam/NL
  • 12 Division Of Internal Medicine (mod) And Oncogenomics, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 13 Department Of Nuclear Medicine, St Antonius Hospital, 3435CM - Nieuwegein/NL
  • 14 Institute Of Health Policy & Management, Institute for Medical Technology Assessment, Erasmus University, 3062 PA - Rotterdam/NL
  • 15 Department Of Medical Oncology, Radboud University Medical Center, 6525 XZ - Nijmegen/NL
More

Resources

Background

Data on outcomes of a 3rd line life prolonging drug (LPD) in patients with metastatic castration resistant prostate cancer (mCRPC) is lacking. Aim of this study was to evaluate outcomes of a 3rd LPD in a real-world cohort of mCRPC patients.

Methods

mCRPC patients with a 3rd LPD before July 1st 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed to December 31st 2017. Outcomes were overall survival (OS), treatment duration (TD) and PSA response. The association of potential risk factors with death was tested by Cox proportional-hazard models after multiple imputation of missing baseline characteristics.

Results

We identified 602 patients treated with a 3rd LPD. Baseline characteristics are listed in the table. Median OS was 7.8 mo (IQR 4.4-14.0), median TD was 3.2 mo (IQR 1.9-4.7) and PSA response (≥ 50% decline) was observed in 131 patients (22%). ECOG PS of 1 and >1 (HR 1.48, p < 0.01 and HR 1.75, p < 0.01, respectively), opioid use (HR 1.51, p < 0.01), symptoms (HR 1.50, p = 0.04), visceral metastases (HR 2.11, p < 0.01), PSA ≥170 ug/l (HR 1.32, p < 0.01), alkaline phosphatase ≥150 U/l (HR 1.66, p < 0.01) and time from CRPC to start 3rd LPD <24 mo (HR 1.56, p < 0.01) were related to shorter survival in multivariable analysis. Patients were categorized into low (0-1 point, n = 81), low-intermediate (2-3 points, n = 262), high-intermediate (4-5 points, n = 208) and high risk (6-7 points, n = 51) prognosis groups based on the number of prognostic factors and their regressions coefficients. These groups had a median OS of 20.4, 11.0, 6.6 and 3.9 mo, with a median TD of 4.6, 3.4, 2.6 and 1.9 mo, respectively (p < 0.01).Table:

865P Baseline characteristics at start of a 3rd line line prolonging drug (LPD) treatment

Characteristics3rd LPD n = 602Missings n(%)
Age (years) a71.1 ± 7.40
Time from CRPC to start treatment (months) b24.6 (16.7-34.1)0
Time from castration to CRPC (months) b13.0 (7.8-23.2)0
ECOG PS132 (21.9)
- 0103 (17.1)
- 1278 (46.2)
->189 (14.8)
Opioid use c153 (25.4)66 (11.0)
Symptomatic c466 (77.4)50 (8.3)
Metastatic site c
- Bone536 (89.0)46 (7.6)
- Visceral102 (16.9)260 (43.1)
- Lymphnode263 (43.7)208 (43.5)
Hemoglobin (mmol/l) a7.2 ± 1.154 (9.0)
Platelets (109/L) b253 (199.0-320.7)62 (10.3)
Prostate-specific antigen (ug/l) b170 (60.9-470.5)37 (6.1)
Alkaline phosphatase (U/l) b153 (90.5-301.0)61 (10.1)
Lactate dehydrogenase (U/l) b261 (207.5-383.0)144 (23.9)
3rd line LPD treatment c
- Abiraterone acetate137 (22.8)0
- Enzalutamide129 (21.4)0
- Docetaxel45 (7.5)0
- Cabazitaxel213 (35.4)0
- Radium-223-chloride78 (13.0)0

Note: Data are defined as amean ± SD, bmedian (IQR) or cnumber of patients (%). Abbreviations: CRPC; Castration-resistant prostate Cancer, ECOG PS;

Eastern Cooperative Oncology Group Performance Score.

Conclusions

Our results show that the efficacy of a 3rd LPD in mCRPC patients was limited compared to pivotal trials of 1st and 2nd line. We used a simple prognostic model to identify mCRPC patients that can benefit from a 3rd LPD.

Clinical trial identification

NL3440 (NTR3591).

Editorial acknowledgement

Legal entity responsible for the study

Institute for Medical Technology Assessment, Erasmus University Rotterdam.

Funding

Sanofi-Aventis Netherlands B.V., Janssen-Cilag B.V., Astellas Pharma B.V., Bayer B.V.

Disclosure

M.C.P. Kuppen: Travel / Accommodation / Expenses: Ipsen. H.M. Westgeest: Travel / Accommodation / Expenses: Ipsen; Honoraria (self): Roche. A.J.M. van den Eertwegh: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD Oncology; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Ipsen; Honoraria (institution), Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Amgen; Advisory / Consultancy: Novartis; Advisory / Consultancy: Merck. J. Van Moorselaar: Honoraria (institution), Advisory / Consultancy: Amgen; Honoraria (institution), Advisory / Consultancy: Astellas; Honoraria (institution), Advisory / Consultancy: AstraZeneca; Honoraria (institution), Advisory / Consultancy: Bayer; Honoraria (institution), Advisory / Consultancy: Janssen; Honoraria (institution), Advisory / Consultancy: Sanofi-Genzyme. N. Mehra: Research grant / Funding (institution): Astellas; Honoraria (self), Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Sanofi; Honoraria (self), Research grant / Funding (institution): Roche; Honoraria (self): Merck; Honoraria (self): Bayer; Honoraria (self): BMS; Honoraria (self): MSD. J.L. Coenen: Advisory / Consultancy: Sanofi. I. van Oort: Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Roche; Advisory / Consultancy: Mdx Health; Advisory / Consultancy: Astellas. D.M. Somford: Research grant / Funding (institution): Astellas. R. de Wit: Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (institution), Advisory / Consultancy: Merck; Honoraria (institution), Advisory / Consultancy: Sharp&Dohme; Advisory / Consultancy: Roche/ Genentech; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Clivis; Travel / Accommodation / Expenses: Lilly. A.M. Bergman: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Speaker Bureau / Expert testimony: Janssen. C. Uyl-de Groot: Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Janssen-Cilag; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Genzyme; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Glycostem Therapeutics; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Merck. W.R. Gerritsen: Advisory / Consultancy, Speaker Bureau / Expert testimony: Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Bavarian Nordic; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony: Janssen-Cilag; Advisory / Consultancy: Amgen; Advisory / Consultancy: Merck; Advisory / Consultancy: Morphosys; Advisory / Consultancy: Sanofi; Advisory / Consultancy, Ad hoc Consultancy: Aglaia Biomedical Ventures; Advisory / Consultancy, Ad hoc Consultancy: Psioxus Therapeutics; Advisory / Consultancy: Curvevac; Advisory / Consultancy: Dendreon. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings